EGFR and non-small cell lung carcinoma: <b>Patients and Methods:</b> Two patients with unresectable advanced NSCLC were enrolled into the National Institutes of Health Clinical Center (NIHCC) Study (ClinicalTrials.gov: 16-C-0092; local ablative therapy for the treatment of oligoprogressive, <i>EGFR</i>-mutated, non-small cell lung cancer after treatment with osimertinib).